ReviewAdvances in experimental medicine and biology2025
Viral Safety.
Review in Advances in experimental medicine and biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Viral safety is an extremely important issue for the clinical application of cell therapy products. The viral contamination of products can lead to serious adverse events in patients treated with them. Therefore, it is strongly recommended to evaluate the viral safety of products using the most advanced science and technology available at the time, based on scientific rationality. We are also obligated to respond to society's strong interest in and social demand for public health preservation. Because various types of cell therapy products have been developed, some measures to ensure viral safety for each product are common, and others should be addressed on a case-by-case basis. This chapter outlines the basic approach for viral safety confirmation for cell therapy products and introduces our recent work on viral safety using the next-generation sequencer.
Indexed as
Identifiers
41136852What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.